Released Feb 23, 2021, after the close
10-K filed Feb 23, 2021, 54 days after period end · 0001232524-21-000016
Q4 2020 · 10-K
Revenue$665.52M$665.52M +14.4% vs Q4 2019+10.8% vs Q3 2020
Net Income$133.41M$133.41M +80.3% vs Q4 2019−10.0% vs Q3 2020
EPS Diluted$2.33$2.33 +80.6% vs Q4 2019−11.7% vs Q3 2020
Gross Profit$611,146,000+12.9%
Operating Incomederived$173,414,000+183.1%
Operating Cash Flowderived$186,271,000+112.2%
Free Cash Flowderived$182,156,000+125.8%
Margins · derived
Gross margin91.8%−1.2 pt vs Q4 2019
Operating margin26.1%+15.5 pt vs Q4 2019
Net margin20.0%+7.3 pt vs Q4 2019
What the release said
The release
Same quarter
| Metric | Q4 2020 | Q4 2019 | Q4 2018 | Q4 2017 |
|---|---|---|---|---|
| Revenue | $665.52M | $581.74M | $476.46M | $436.40M |
| Net Income | $133.41M | $73.99M | $159.47M | $232.21M |
| EPS Diluted | $2.33 | $1.29 | $2.64 | $3.79 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Jazz Pharmaceuticals plc · CIK 1232524 · Engraved from SEC EDGAR